Cormorant Asset Management’s Epizyme, Inc EPZM Stock Holding History

Cormorant Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-140,000	Closed	-$2.4M	–	81
2017 Q1	$2.4M	Sell	140,000 -19,513	-12%	-$260K	0.35%	55
2016 Q4	$1.93M	Hold	159,513	–	–	0.26%	62
2016 Q3	$1.57M	Hold	159,513	–	–	0.17%	68
2016 Q2	$1.63M	Sell	159,513 -106,737	-40%	-$1.19M	0.23%	64
2016 Q1	$3.23M	Hold	266,250	–	–	0.49%	50
2015 Q4	$4.26M	Hold	266,250	–	–	0.51%	47
2015 Q3	$3.42M	Hold	266,250	–	–	0.55%	47
2015 Q2	$6.39M	Hold	266,250	–	–	0.85%	35
2015 Q1	$5M	Buy	+266,250	New	+$5.5M	0.77%	41

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cormorant Asset Management's EPZM Position: Q2 2017 in Review

Cormorant Asset Management sold out of Epizyme, Inc (EPZM) in Q2 2017, closing a stake of 140,000 shares — an estimated $2.4M sold.

Cormorant Asset Management first reported a position in EPZM in Q1 2015 and held it in 9 quarters. The position peaked at $6.39M in Q2 2015. 108 funds tracked by Wall St. Rank hold EPZM as of Q2 2017.

Cormorant Asset Management reported no remaining Epizyme, Inc position as of Q2 2017 after selling out during the quarter.
Cormorant Asset Management sold 140,000 Epizyme, Inc shares in Q2 2017, an estimated $2.4M.
Cormorant Asset Management first reported a position in Epizyme, Inc in Q1 2015 and held it in 9 quarters.
Cormorant Asset Management's Epizyme, Inc position peaked at $6.39M in Q2 2015.
108 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.